Head And Neck Cancer – Pipeline Review, H1 2018
- Pages: 1639
- Published: April 2018
- Report Code: GMDHC10354IDB
Global Markets Direct’s, ‘Head And Neck Cancer – Pipeline Review, H1 2018’, provides an overview of the Head And Neck Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer
– The report reviews pipeline therapeutics for Head And Neck Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Head And Neck Cancer therapeutics and enlists all their major and minor projects
– The report assesses Head And Neck Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
3SBio Inc
4SC AG
AbbVie Inc
Abion Inc
Adaptimmune Therapeutics Plc
Admedus Ltd
Aduro BioTech Inc
Advaxis Inc
Advenchen Laboratories LLC
Affimed GmbH
Altor BioScience Corp
Ambrx Inc
amcure GmbH
Amgen Inc
arGEN-X BV
ArQule Inc
Array BioPharma Inc
Ascentage Pharma Group Corp Ltd
Aspyrian Therapeutics Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Aurigene Discovery Technologies Ltd
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
Benitec Biopharma Ltd
Bexion Pharmaceuticals LLC
Bicycle Therapeutics Ltd
BioDiem Ltd
Biohaven Pharmaceutical Holding Company Ltd
Biomics Biotechnologies Co Ltd
Bionovis SA
BioNTech AG
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
CBT Pharmaceuticals Inc
CEL-SCI Corp
Celgene Corp
Cell Medica Ltd
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celprogen Inc
Checkpoint Therapeutics Inc
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
Cristal Therapeutics BV
Curevac AG
Cyclacel Pharmaceuticals Inc
CytImmune Sciences Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Denceptor Therapeutics Ltd
DNJ Pharma Inc
Dynavax Technologies Corp
Eisai Co Ltd
Eli Lilly and Co
Enzene Biosciences Ltd
Etubics Corp
Eureka Therapeutics Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Formation Biologics Inc
Forty Seven Inc
Fujifilm Holdings Corporation
G&E Herbal Biotechnology Co Ltd
Galectin Therapeutics Inc
Genelux Corp
Genentech Inc
GeneSegues Inc
Genmab A/S
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Gliknik Inc
Glycotope GmbH
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hookipa Biotech AG
Horizon Pharma Plc
Hutchison MediPharma Ltd
Idera Pharmaceuticals Inc
Ignyta Inc
Immatics Biotechnologies GmbH
Immunocore Ltd
Immunomedics Inc
Immunovaccine Inc
Immunovative Therapies Ltd
Immutep Ltd
Incyte Corp
Infinity Pharmaceuticals Inc
Innate Pharma SA
Inovio Pharmaceuticals Inc
InteRNA Technologies BV
Iovance Biotherapeutics Inc
IRX Therapeutics Inc
ISA Pharmaceuticals BV
ISU ABXIS Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Jounce Therapeutics Inc
Juno Therapeutics Inc
Kite Pharma Inc
Kura Oncology Inc
Laboratoires Pierre Fabre SA
LATITUDE Pharmaceuticals Inc
Loxo Oncology Inc
Lycera Corp
Lytix Biopharma AS
Mabion SA
MacroGenics Inc
Madrigal Pharmaceuticals Inc.
Marsala Biotech Inc
Mateon Therapeutics Inc
MaxiVAX SA
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Moderna Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech Inc
NanoCarrier Co Ltd
NantKwest Inc
Natco Pharma Ltd
NeoImmuneTech Inc
Neonc Technologies Inc
Neumedicines Inc
Novartis AG
Noxopharm Ltd
Oncobiologics Inc
Oncolys BioPharma Inc
Onconova Therapeutics Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Otsuka Holdings Co Ltd
Oxford Vacmedix UK Ltd
PDS Biotechnology Corp
Pfizer Inc
Pharma Mar SA
Phosplatin Therapeutics LLC
Plexxikon Inc
PNP Therapeutics Inc
Profectus BioSciences Inc
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
R Pharm
Regeneron Pharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Sareum Holdings Plc
Selecta Biosciences Inc
Shanghai Henlius Biotech Co Ltd
Shionogi & Co Ltd
Sierra Oncology Inc
Sillajen Biotherapeutics
Sinil Pharmaceutical Co Ltd
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Sound Pharmaceuticals Inc
Spherium Biomed SL
Sumitomo Dainippon Pharma Co Ltd
SuviCa Inc
SynCore Biotechnology Co Ltd
Systimmune Inc
Takis Srl
Tessa Therapeutics Pte Ltd
Theralase Technologies Inc
Theravectys SA
Tolero Pharmaceuticals Inc
Tosk Inc
Transgene SA
UbiVac LLC
Vaccibody AS
VasGene Therapeutics Inc
Vault Pharma Inc
Vaxeal Holding SA
Vectorite Biomedical Inc
Viracta Therapeutics Inc
Vyriad Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.